269 related articles for article (PubMed ID: 9031099)
1. Chlorambucil in chronic lymphocytic leukemia: mechanism of action.
Begleiter A; Mowat M; Israels LG; Johnston JB
Leuk Lymphoma; 1996 Oct; 23(3-4):187-201. PubMed ID: 9031099
[TBL] [Abstract][Full Text] [Related]
2. P53, MDM-2, BAX and BCL-2 and drug resistance in chronic lymphocytic leukemia.
Johnston JB; Daeninck P; Verburg L; Lee K; Williams G; Israels LG; Mowat MR; Begleiter A
Leuk Lymphoma; 1997 Aug; 26(5-6):435-49. PubMed ID: 9389352
[TBL] [Abstract][Full Text] [Related]
3. Bcl-2 protein expression and p53 gene mutation in chronic lymphocytic leukemia: correlation with in vitro sensitivity to chlorambucil and purine analogs.
Morabito F; Filangeri M; Callea I; Sculli G; Callea V; Fracchiolla NS; Neri A; Brugiatelli M
Haematologica; 1997; 82(1):16-20. PubMed ID: 9107076
[TBL] [Abstract][Full Text] [Related]
4. In vitro cytotoxicity of 2-chlorodeoxyadenosine and chlorambucil in chronic lymphocytic leukemia.
Begleiter A; Wang H; Verburg L; Lee K; Israels LG; Mowat MR; Johnston JB
Leukemia; 1996 Dec; 10(12):1959-65. PubMed ID: 8946937
[TBL] [Abstract][Full Text] [Related]
5. Chlorambucil induction of HsRad51 in B-cell chronic lymphocytic leukemia.
Christodoulopoulos G; Malapetsa A; Schipper H; Golub E; Radding C; Panasci LC
Clin Cancer Res; 1999 Aug; 5(8):2178-84. PubMed ID: 10473103
[TBL] [Abstract][Full Text] [Related]
6. Cross-resistance and synergy with bendamustine in chronic lymphocytic leukemia.
Kost SE; Bouchard ED; LaBossière É; Ye X; Queau ML; Liang WS; Banerji V; Gibson SB; Katyal S; Johnston JB
Leuk Res; 2016 Nov; 50():63-71. PubMed ID: 27683974
[TBL] [Abstract][Full Text] [Related]
7. Drug resistance mechanisms in chronic lymphocytic leukemia.
Ribrag V; Massade L; Faussat AM; Dreyfus F; Bayle C; Gouyette A; Marie JP
Leukemia; 1996 Dec; 10(12):1944-9. PubMed ID: 8946935
[TBL] [Abstract][Full Text] [Related]
8. Imatinib sensitizes CLL lymphocytes to chlorambucil.
Aloyz R; Grzywacz K; Xu ZY; Loignon M; Alaoui-Jamali MA; Panasci L
Leukemia; 2004 Mar; 18(3):409-14. PubMed ID: 14712290
[TBL] [Abstract][Full Text] [Related]
9. Chemosensitivity of lymphocytes from patients with B-cell chronic lymphocytic leukemia to chlorambucil, fludarabine, and camptothecin analogs.
Silber R; Degar B; Costin D; Newcomb EW; Mani M; Rosenberg CR; Morse L; Drygas JC; Canellakis ZN; Potmesil M
Blood; 1994 Nov; 84(10):3440-6. PubMed ID: 7949099
[TBL] [Abstract][Full Text] [Related]
10. Bax expression correlates with cellular drug sensitivity to doxorubicin, cyclophosphamide and chlorambucil but not fludarabine, cladribine or corticosteroids in B cell chronic lymphocytic leukemia.
Bosanquet AG; Sturm I; Wieder T; Essmann F; Bosanquet MI; Head DJ; Dörken B; Daniel PT
Leukemia; 2002 Jun; 16(6):1035-44. PubMed ID: 12040435
[TBL] [Abstract][Full Text] [Related]
11. Potentiation of chlorambucil cytotoxicity in B-cell chronic lymphocytic leukemia by inhibition of DNA-dependent protein kinase activity using wortmannin.
Christodoulopoulos G; Muller C; Salles B; Kazmi R; Panasci L
Cancer Res; 1998 May; 58(9):1789-92. PubMed ID: 9581813
[TBL] [Abstract][Full Text] [Related]
12. Chlorambucil drug resistance in chronic lymphocytic leukemia: the emerging role of DNA repair.
Panasci L; Paiement JP; Christodoulopoulos G; Belenkov A; Malapetsa A; Aloyz R
Clin Cancer Res; 2001 Mar; 7(3):454-61. PubMed ID: 11297233
[TBL] [Abstract][Full Text] [Related]
13. DNA-Dependent protein kinase activity correlates with clinical and in vitro sensitivity of chronic lymphocytic leukemia lymphocytes to nitrogen mustards.
Muller C; Christodoulopoulos G; Salles B; Panasci L
Blood; 1998 Oct; 92(7):2213-9. PubMed ID: 9746757
[TBL] [Abstract][Full Text] [Related]
14. High dose chlorambucil versus Binet's modified cyclophosphamide, doxorubicin, vincristine, and prednisone regimen in the treatment of patients with advanced B-cell chronic lymphocytic leukemia. Results of an international multicenter randomized trial. International Society for Chemo-Immunotherapy, Vienna.
Jaksic B; Brugiatelli M; Krc I; Losonczi H; Holowiecki J; Planinc-Peraica A; Kusec R; Morabito F; Iacopino P; Lutz D
Cancer; 1997 Jun; 79(11):2107-14. PubMed ID: 9179056
[TBL] [Abstract][Full Text] [Related]
15. In vitro sensitivity of chronic lymphocytic leukemia B-cells to fludarabine, 2-chlorodeoxyadenosine and chlorambucil: correlation with clinico-hematological and immunophenotypic features.
Morabito F; Stelitano C; Callea I; Filangeri M; Oliva B; Sculli G; Callea V; Nobile F; Brugiatelli M
Haematologica; 1996; 81(3):224-31. PubMed ID: 8767527
[TBL] [Abstract][Full Text] [Related]
16. The effect of chlorambucil treatment on cytogenetic parameters in chronic lymphocytic leukemia patients.
Amiel A; Biton I; Yukla M; Gaber E; Fejgin MD; Lishner M
Cancer Genet Cytogenet; 2003 Jun; 143(2):113-9. PubMed ID: 12781444
[TBL] [Abstract][Full Text] [Related]
17. Role of the TRAIL/APO2-L death receptors in chlorambucil- and fludarabine-induced apoptosis in chronic lymphocytic leukemia.
Johnston JB; Kabore AF; Strutinsky J; Hu X; Paul JT; Kropp DM; Kuschak B; Begleiter A; Gibson SB
Oncogene; 2003 Nov; 22(51):8356-69. PubMed ID: 14614459
[TBL] [Abstract][Full Text] [Related]
18. Chlorambucil resistance in B-cell chronic lymphocytic leukaemia is mediated through failed Bax induction and selection of high Bcl-2-expressing subclones.
Pepper C; Thomas A; Hoy T; Bentley P
Br J Haematol; 1999 Mar; 104(3):581-8. PubMed ID: 10086798
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy with nucleoside analogs and alkylating agents.
Johnston JB; Verburg L; Shore T; Williams M; Israels LG; Begleiter A
Leukemia; 1994 Apr; 8 Suppl 1():S140-3. PubMed ID: 8152282
[TBL] [Abstract][Full Text] [Related]
20. Bcl-2 and bax expression and chlorambucil-induced apoptosis in the T-cells and leukaemic B-cells of untreated B-cell chronic lymphocytic leukaemia patients.
Thomas A; Pepper C; Hoy T; Bentley P
Leuk Res; 2000 Oct; 24(10):813-21. PubMed ID: 10996199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
